An antibody, antigen binding fragment thereof or a pharmaceutical formulation, which is an inhibitor of signalling through IL-13Rα1 by binding said receptor and compositions comprising the same for use in the treatment of atopic dermatitis (for example moderate to severe atopic dermatitis, in particular poorly controlled moderate to severe atopic dermatitis) by parenteral administration of a treatment cycle comprising a dose in the range 200 mg to 600 mg, (such as 400 to 600 mg), wherein the disease is modified by a percentage reduction in EASI score in the range −20 to −100% from the baseline.

The present invention describes compounds of formula (I) ##STR00001##
Wherein:
R.sup.1 is selected from H and CH.sub.3
R.sup.2 is selected from H, C.sub.4H.sub.9 alkyl, C.sub.6H.sub.13 alkyl and C.sub.3H.sub.6-phenyl, said phenyl optionally substituted by OH or OCH.sub.3, (1R,2S,5S)-5-methylcyclopent-3-ene-1,2-diol
X is O or S
Y is C, N or S. These compounds have been identified as novel compounds useful in the treatment of multiple sclerosis and other autoimmune diseases.

The present invention describes compounds of formula (I) ##STR00001##
Wherein:
R.sup.1 is selected from H and CH.sub.3
R.sup.2 is selected from H, C.sub.4H.sub.9 alkyl, C.sub.6H.sub.13 alkyl and C.sub.3H.sub.6-phenyl, said phenyl optionally substituted by OH or OCH.sub.3, (1R,2S,5S)-5-methylcyclopent-3-ene-1,2-diol
X is O or S
Y is C, N or S. These compounds have been identified as novel compounds useful in the treatment of multiple sclerosis and other autoimmune diseases.

The present disclosure relates to compounds that are Syk inhibitors or pharmaceutically acceptable salts or co-crystals thereof, and pharmaceutical compositions thereof, and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, a Syk inhibitor is a crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo-[1,2-a]pyrazin-8-amine of formula 2: ##STR00001##

The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.

The present disclosure relates to methods for modulating the level of proteins in a subject or in target cells by priming red blood cells with various agents or conditions that modulate the levels of proteins associated with red blood cells and administering the primed red blood cells to a subject. The disclosed methods represent a novel use of red blood cells primed to express a number of proteins, as cell therapies for numerous diseases or disorders.

Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections. ##STR00001##

Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections. ##STR00001##

Provide are beneficial bacteria that can be beneficially applied across a wide range of age groups and a composition containing the same. Bifidobacterium longum subspecies longum NITE BP-02568 and/or Bifidobacterium longum subspecies longum NITE BP-02569; and Bifidobacterium longum subspecies longum, having utilization ability for 2′-fucosyllactose are also provided. More preferably, bacteria having utilization ability for carbohydrates arabinoxylan, arabinan, and pectic galactan; and a composition containing the bacteria are also provided. More preferably, a composition containing 2′-fucosyllactose are also provided. More preferably, a composition containing at least one carbohydrate selected from the group consisting of arabinoxylan, arabinan, pectic galactan, and oligosaccharides derived therefrom or containing at least a carbohydrate derived from a gramineous plant or a carbohydrate derived from a solanaceous plant are also provided.

Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.